For the quarter ending 2025-12-31, ENTA made $18,615K in revenue. -$11,938K in net income. Net profit margin of -64.13%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenue | 18,615 | 15,464* | 18,314 | 14,926 |
| Research and development | 20,859 | 23,827* | 27,210 | 28,065 |
| General and administrative | 9,009 | 11,856* | 9,997 | 11,388 |
| Total operating expenses | 29,868 | 35,682* | 37,207 | 39,453 |
| Loss from operations | -11,253 | -20,218* | -18,893 | -24,527 |
| Interest expense | 3,083 | 2,653* | 1,618 | 1,714 |
| Interest and investment income, net | 2,422 | 2,577* | 2,285 | 2,292 |
| Change in fair value of series 1 nonconvertible preferred stock | - | 10* | - | - |
| Total other (expense) income, net | -661 | -67* | 667 | 578 |
| Loss before income taxes | -11,914 | -20,286* | -18,226 | -23,949 |
| Income tax (expense) benefit | 24 | 254* | 29 | -1,305 |
| Net loss | -11,938 | -20,540 | -18,255 | -22,644 |
| Basic EPS | -0.42 | 0.481 | -0.85 | -1.06 |
| Diluted EPS | -0.42 | 0.481 | -0.85 | -1.06 |
| Basic Average Shares | 28,748,000 | -42,667,992 | 21,377,000 | 21,355,000 |
| Diluted Average Shares | 28,748,000 | -42,667,992 | 21,377,000 | 21,355,000 |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)